Cat-Allergy Shot From Circassia May Limit Need for Pill-Popping

Cat-Allergy Shot From Circassia May Limit Need for Pill-Popping

Torsten Silz/AFP/Getty Images

Circassia Holdings Ltd. is awaiting approval from U.S. regulators to begin a $33 million final-stage trial of its cat-allergy vaccine on 1,200 people in September or October, Chief Executive Officer Steven Harris says.